Pharma Focus Asia

Pfizer Announces Approval of ABRYSVO™

Thursday, June 01, 2023

Pfizer has recently made an announcement regarding the approval of ABRYSVO™ (Respiratory Syncytial Virus Vaccine) by the U.S. Food and Drug Administration (FDA). This approval signifies that ABRYSVO™ is now authorised for the prevention of lower respiratory tract disease caused by RSV specifically in individuals who are 60 years and older. 

ABRYSVO is an unadjuvanted vaccine that consists of two preF proteins. These proteins are specifically chosen to enhance protection against respiratory syncytial virus (RSV) strains A and B. The vaccine has undergone studies and has been observed to be both safe and effective.

The primary goal of ABRYSVO is to address the need for better protection against RSV disease in older adults. RSV can cause severe respiratory illness, especially in older individuals who may have weaker immune systems. 

By targeting both RSV A and B strains and using optimised preF proteins, ABRYSVO aims to provide enhanced protection against the potentially serious consequences of RSV infection.

The recent FDA approval of ABRYSVO is a testament to remarkable advancements in science. It offers older adults a promising shield against RSV (Respiratory Syncytial Virus) while also presenting an opportunity to enhance community well-being by mitigating the spread of this illness.
 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024